人のウォール街のアナリストによると、Nu-Med Plus Incの収益見積もりは$から$の範囲です。
Nu-Med Plus Incの収益品質スコアはどれくらいですか?
Nu-Med Plus Incの収益品質スコアはB/41.283085です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Nu-Med Plus Incはいつ収益を報告しますか?
Nu-Med Plus Incの次の収益報告は2026-08-18に予定されています
Nu-Med Plus Incの予想収益はいくらですか?
ウォール街のアナリストによると、Nu-Med Plus Incの予想収益は$です。
Nu-Med Plus Incは収益予想を上回りましたか?
Nu-Med Plus Incの最近の収益は$で、予想を。
主要データ
前終値
$0.011
始値
$0.011
当日レンジ
$0.011 - $0.011
52週レンジ
$0.0097 - $0.06
取引高
1.0K
平均取引高
24.7K
配当利回り
--
1株当たり利益(TTM)
-0.00
時価総額
$919.0K
NUMDとは何ですか?
Nu-Med Plus, Inc. engages in the design, development, and marketing of technologies utilizing nitric oxide in the medical device field. The company is headquartered in Salt Lake City, Utah and currently employs 2 full-time employees. The company went IPO on 2013-08-02. The company focuses on the creation of a nitric oxide (NO) generating formulation, a hospital bedside NO delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. The Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery offers a range of concentrations and flow rates of NO.